BioDuro Secures Two EcoVadis Gold Medals for Sustainability Excellence

In addition to rebranding itself from BioDuro-Sundia, BioDuro, the global contract research, development and manufacturing organization (CRDMO) announced it has achieved Gold Medal ratings in the 2024 EcoVadis sustainability assessment for its Jiangsu and Shanghai Free Trade Zone (FTZ) sites in China.

EcoVadis provide independent sustainability ratings to companies based on themes of environmental stewardship, ethics, labor, human rights and sustainable purchasing, and the scores achieved placed the Jiangsu site among the top 3%, and Shanghai within the top 5% of evaluated companies.

BioDuro provides advanced oral dosage pre-formulation, formulation development, and manufacturing services from Jiangsu, while its Shanghai site has recently launched a compound management center to support its integrated discovery services.

BioDuro, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its sites in Jiangsu and the Shanghai Free Trade Zone (FTZ) in China have each been awarded a Gold Medal in the 2024 EcoVadis business sustainability assessment, placing them among the top 3% and 5% of the companies it has evaluated in the last 12 months, respectively. These achievements underscore BioDuro’s dedication to sustainability and its proactive approach to integrating environmental and social responsibility into its business strategies and operations.

“Achieving the EcoVadis Gold Rating highlights BioDuro’s exceptional performance in the themes of environmental stewardship, ethics, labor and human rights, and sustainable procurement,” said Dr. Armin Spura, CEO of BioDuro. “With nearly three decades of success in the CDMO industry, we remain steadfast in upholding the highest standards of compliance and quality as we work to create enduring value for our employees, suppliers, clients, and society.”

The Gold-rated Jiangsu and Shanghai FTZ sites are an integral part of BioDuro’s global CRDMO network. Each leverages its broad expertise in biology, drug metabolism and pharmacokinetics (DMPK), and chemistry to offer comprehensive and integrated drug discovery services, spanning from target to hit, hit to lead, until preclinical compound selection. The Jiangsu site also provides advanced oral dosage pre-formulation, formulation development, and manufacturing services, and the site in the Shanghai FTZ has recently launched a compound management center, enhancing its operational efficiency.

For more, please find the original story source here.